In France malaria is monitored by the Centre National de Référence (CNR) du Paludisme (French National Malaria Reference Centre). The annual incidence of imported malaria currently ranges from 4 800 to 3 500 cases and has fallen gradually since 2000. However, the proportion of patients with severe P. falciparum malaria is increasing (2.5% in 2000, 7% in 2011), particularly among French residents from sub-Saharan Africa who neglect preventive measures. Overall mortality remains stable at 0.4%, but survival is improving in severe cases. The survival rate is higher among patients of African origin than among Europeans. Nonetheless, between 10 and 20 patients die of malaria every year in France. Two large controlled trials published in 2005 and 2010 showed that IV artesunate, a new treatment for severe falciparum malaria, is associated with a 22-38% absolute reduction in mortality relative to quinine. Artesunate is not licensed in Europe but has been available in France since May 2011 through a named-patient program controlled by the French Agency for Drug Safety [ANSM]. The first 99 patients treated with artesunate up to September 2012 experienced satisfactory efficacy and tolerability. Delayed, sometimes persistent anemia was observed in 13 patients, a rate similar to that noted in recent reports on imported malaria in Europe. This unexpected adverse effect requires further investigation. IV artesunate is now recommended as the first-line treatment for severe falciparum malaria in France.